Another critical point to consider is that APSMR‐mediated HT combined with RT may elevate PD‐L1 expression in melanoma,[46, 47] thereby boosting the efficacy of anti–PD‐L1 immune checkpoint therapy and overcoming the limitations of single therapeutic strategies. This evidence concerns the gene CD274 and melanoma.